WHO Updated guideline on tuberculosis preventive treatment contains new recommendations and covers critical steps in programmatic management that follow the cascade of preventive care. The main changes include conditional recommendations for a 1-month daily rifapentine and isoniazid regimen and a 4-month daily rifampicin regimen as alternative treatment options in all TB burden settings. Advice on isoniazid preventive treatment in pregnancy and on the concomitant use of rifapentine and dolutegravir has been updated. The operational limitations that need to be overcome by countries to achieve global targets are highlighted but are in greater detail in the accompanying operational handbook that is released concurrently. The guidelines are to be used primarily in national TB and HIV programmes.
